Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.

Slides:



Advertisements
Similar presentations
Vertical versus Decentralized TB Pharmaceutical Management
Advertisements

Group III: Demand Forecasting
Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.
EPI in development: HepB/Hib combination vaccine tender overview Pre-tender meeting UNICEF Supply Division, December 2008 Meredith Shirey.
TB and HIV: Tightly Linked… and Why We Should Care.
Dr. Samiha Baghdadi – Medical officer EMRO –STB ICIUM - Antalya November 2011.
Adrienn Nagy dr. Leader Corporate Services Business Supervision and Process Management Budapest 14/11/2007 Procurement Audits.
The Role of the IATT Optimal Paediatric ARV Formulary and Considerations for New Product Introduction Nandita Sugandhi, M.D. Clinton Health Access Initiative.
Manila, Dec.2014 NEW DRUGS INTRODUCTION IN VIETNAM – SHORT PROGRESS UPDATE.
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
TBS Meeting Geneva, November 2011 Global Fund Policies and Reporting on Procurement of Health Products WHO/UNICEF Technical Briefing Seminar on Essential.
1 Procurement of ACT's Informal Workshop on Prequalification of Antimalarial Drug Products Geneva, 5 th May 2004 WHO/UNICEF JOINT REQUEST FOR PROPOSALS.
Management of the Tuberculosis Drug Supply Module 13 – March 2010.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
Essential Medicines Programmes Sudan now Essential Medicines Programmes Sudan now.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
World Health Organization
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
REDUCTION OF ‘OUT OF POCKET’ EXPENSES OF PATIENTS THROUGH INNOVATIVE PRACTICES OF THE GOVERNMENT OF WEST BENGAL.
Health Care In Latvia Current Situation And Challenges In the Future Ingrīda Circene Minister for Health of the Republic of Latvia Riga,
MINISTRY OF PUBLIC HEALTH AND SOCIAL WELFARE EL SALVADOR, CENTRAL AMERICA EXPERIENCE WITH CONTRACEPTIVE PROCUREMENT Ministry of Health, El Salvador OCTOBER.
Programmatic Management of Multidrug Resistant TB (PMDT) 5 th Joint International Monitoring Mission of NTP, Thailand 23 August, 2013.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
GLOBAL DRUG FACILITY Improving country access to anti-TB medicines Andrea de Lucia, GDF Team Leader 1 st line Country Support WHO/UNICEF Technical Briefing.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Progress to date and Plans for Year 5 Overcoming HIV/AIDS epidemic in Ukraine Programme supported by the Global Fund 11 th Stakeholders’ meeting 22 nd.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
Price Considerations for TB Drugs. Goals of Effective Procurement Selecting appropriate medicines Meeting required quality standards In right quantities.
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
What do we mean with ‘ there is no access to Paediatric ARV Formulations ’ ?
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 7: GAP BETWEEN AVAILABILTY OF DRUG SUSCEPTIBILITY.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Working Draft - Last Modified :21:46 Printed UNITAID action plan - pediatric TB 0 “Securing timely access to quality, affordable TB drugs”
October 31, 2014 Satellite Symposium: The pediatric TB drug market: progress and future direction Market understanding: new data on the purchasing habits.
Procurement &supply chain management 5 th Joint International Monitoring Mission.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
1 Global Drug Facility presentation IPC meeting 10 December 2015 Magali Babaley Procurement, supply and country support manager.
Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility.
DG Justice and Consumers Project Modifications DG Justice and Consumers.
Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.
Improving Access for Quality-Assured TB Medicines and Diagnostics Medicines and Diagnostics Improving Access for Quality-Assured TB Medicines and Diagnostics.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
Supply Chain Management of Second Line Drugs: Russian Example Dr Vadim V. Testov Central TB Research Institute, Moscow, the Russian Federation.
WHO Estonia country office Marge Reinap Head of WHO Country Office in Estonia.
Improving Access for Quality-Assured TB Medicines and Diagnostics Medicines and Diagnostics Improving Access for Quality-Assured TB Medicines and Diagnostics.
Community Representative Update
Procurement and Supply Management Policies
Global Drug Facility An innovative approach to supplying anti-TB drugs
1. Structure and training objectives for this course & key references
Increased access to quality TB drugs
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Global programmatic use of bedaquiline and delamanid for drug-resistant TB treatment: progress, challenges, and possible solutions Dr. Vivian Cox Chair,
Introducing new drugs and shorter regimen
Richard Laing, Kelly McGoldrick
AMDS Products, events and issues.
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
11 iii. Define management and supervision roles and responsibilities
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Working with the Global Drug Facility
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting 18 June 2015 Update on GDF Procurement

Change of the hosting agreement from WHO to UNOPS as from January ChangeChange

3 Live Report reatments+supplied+-+method+Injectable+standard dose+Rev+3.0&userid=GDF_ro&password=gdfread1 SLD Patient treatments supplied by year SLD cumulative Patient treatments supplied per year 6 months IP until 2012, 8 months thereafter SLD Patient treatments supplied per year by regions MDR Treatments delivered

GDF has been able to dramatically reduce the price of Cycloserine capsule, by -66.6% since last 5 years GDF has ensured sustainable supplies of Cs API: there are 3 API manufacturers (Dong A, Shasun and Macleods), with new supplier of South Korea expected to file API PQ around Q Median Cost in USD per capsule Median EXW Price, USD ITB (India) Average weighted price for 2015 ITB (Rest of the World) Price, USD vs 2010 (%) Median Price % Median Price % 2015 ITB (India) % 2015 ITB (ROW) % GDF and Cs price evolution

GDF price reductions: regimen examples

6 Bedaquiline donation program - 1 Bedaquiline will be provided to GDF for provision to patients and organizations in eligible countries- Agreement between USAID and Janssen Janssen : - Provide, free of charge, 30,000 courses of treatment of bedaquiline (100 mg) over a period of 4 years - Make a contribution of additional “gift funds” to be used to help implement the program. - Provide documentation, medical information, and /or education as require to implement donation. USAID : -Finance technical assistance through partners -Provide forecasts to Janssen -Report to Janssen any Adverse Events or special situations

Country eligibility: - GF eligible countries under conditions that they reasonably meet the requirements set out in the WHO Interim Guidance -Donation must be in compliance with all applicable country local laws and regulations -No quota per countries except in CIS countries (still to be determined by Janssen) -No donation in European countries (for instance, Romania, Latvia) Accessing BDQ donation through GDF: - Same process than others SLD (through GDF procurement agent) - Procurement request Form +Annex 1 to be completed - Drugs free of charge but transport + insurance + PA procurement fee still need to be budgeted -Separate Form to be completed in case of need for Technical Assistance (sent to USAID) More detailed information: Bedaquiline donation program - 2

The interim guidance lists five conditions that must be in place if bedaquiline is used to treat adults with MDR-TB: Effective treatment and monitoring: Treatment must be closely monitored for effectiveness and safety, using sound treatment and management protocols approved by relevant national authorities. Proper patient inclusion: Special caution is required when bedaquiline is used in people aged 65 and over, and in adults living with HIV. Use in pregnant women and children is not advised. Informed consent: Patients must be fully aware of the potential benefits and harms of the new drug, and give documented informed consent before embarking on treatment. Adherence to WHO recommendations: All principles on which WHO-recommended MDR-TB treatment regimens are based, must be followed, bedaquiline alone should not be introduced into a regimen in which the companion drugs are failing to show effectiveness. Active pharmacovigilance and management of adverse events: Active pharmacovigilance measures must be in place to ensure early detection and proper management of adverse drug reactions and potential interactions with other drugs. 8 WHO interim guidance on the use of bedaquiline to treat MDR-TB

Challenges continue remain same Less than 3 eligible suppliers per product: -Paediatric formulations (FDCs), RH150/150mg, H300mg -Km, Cm, Clfz, Lnz, Pth, Trz Short shelf life (24 months only): -100% of paediatric formulations (FDCs), -2 out 4 suppliers manufacturing adult FDCs -40% of SLDs Registration related issues: - slow; limited quantities; complex NRA requirements Old drugs: - 2 new anti-TB drugs (Bedaquiline and Delamanide) entered the market in over 35 years

Thank You for Your attention 10